NL930110I2 - Carbazolyl-(4)-oxypropanolamine-derivaten, werkwijze ter bereiding daarvan en geneesmiddelen, die deze verbindingen bevatten. - Google Patents

Carbazolyl-(4)-oxypropanolamine-derivaten, werkwijze ter bereiding daarvan en geneesmiddelen, die deze verbindingen bevatten.

Info

Publication number
NL930110I2
NL930110I2 NL930110C NL930110C NL930110I2 NL 930110 I2 NL930110 I2 NL 930110I2 NL 930110 C NL930110 C NL 930110C NL 930110 C NL930110 C NL 930110C NL 930110 I2 NL930110 I2 NL 930110I2
Authority
NL
Netherlands
Prior art keywords
carbazolyl
compounds
preparation
drugs containing
oxypropanolamine
Prior art date
Application number
NL930110C
Other languages
English (en)
Dutch (nl)
Other versions
NL930110I1 (nl
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6036838&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL930110(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of NL930110I1 publication Critical patent/NL930110I1/nl
Publication of NL930110I2 publication Critical patent/NL930110I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NL930110C 1978-04-13 1993-06-29 Carbazolyl-(4)-oxypropanolamine-derivaten, werkwijze ter bereiding daarvan en geneesmiddelen, die deze verbindingen bevatten. NL930110I2 (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782815926 DE2815926A1 (de) 1978-04-13 1978-04-13 Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel

Publications (2)

Publication Number Publication Date
NL930110I1 NL930110I1 (nl) 1993-10-18
NL930110I2 true NL930110I2 (nl) 1994-12-01

Family

ID=6036838

Family Applications (1)

Application Number Title Priority Date Filing Date
NL930110C NL930110I2 (nl) 1978-04-13 1993-06-29 Carbazolyl-(4)-oxypropanolamine-derivaten, werkwijze ter bereiding daarvan en geneesmiddelen, die deze verbindingen bevatten.

Country Status (23)

Country Link
US (1) US4503067A (en, 2012)
EP (1) EP0004920B1 (en, 2012)
JP (2) JPS54157558A (en, 2012)
AT (1) AT375639B (en, 2012)
AU (1) AU522975B2 (en, 2012)
BG (1) BG61419B2 (en, 2012)
CA (1) CA1129416A (en, 2012)
CS (2) CS227007B2 (en, 2012)
DD (1) DD143607A5 (en, 2012)
DE (2) DE2815926A1 (en, 2012)
DK (1) DK154555C (en, 2012)
ES (1) ES479396A1 (en, 2012)
FI (1) FI70406C (en, 2012)
HK (1) HK2385A (en, 2012)
HU (1) HU179433B (en, 2012)
IL (1) IL57020A (en, 2012)
LT (1) LT2628B (en, 2012)
LU (1) LU88320I2 (en, 2012)
MX (1) MX9203380A (en, 2012)
NL (1) NL930110I2 (en, 2012)
SG (1) SG52284G (en, 2012)
SU (1) SU810079A3 (en, 2012)
ZA (1) ZA791732B (en, 2012)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3131146A1 (de) * 1981-08-06 1983-02-24 Boehringer Mannheim Gmbh, 6800 Mannheim Neue heteroaryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3300933A1 (de) * 1983-01-13 1984-07-19 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von d,l- und d-carazolol als antiglaukommittel sowie arzneimittel, die diese stoffe enthalten
DE3319027A1 (de) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
GB9113802D0 (en) * 1991-06-26 1991-08-14 Smithkline Beecham Plc Medicaments
US5405863A (en) * 1992-12-01 1995-04-11 Smithkline Beecham Corporation Antioxidant cardioprotective use of, and method of treatment using, hydroxycarbazole compounds
ZA938897B (en) * 1992-12-01 1994-08-01 Smithkline Beecham Corp Antioxidant neuroprotective use of and method of treatment using hydroxycarbazole compounds
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
WO1994020096A1 (en) * 1993-03-05 1994-09-15 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beckman Corporation Limited Method of employing carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5393772A (en) * 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US6075040A (en) * 1996-09-05 2000-06-13 Eli Lilly And Company Selective β3 adrenergic agonists
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
DE19628335A1 (de) * 1996-07-13 1998-01-15 Boehringer Mannheim Gmbh Verwendung von Carbazolyl-(4)-oxy-propanolamin-Derivaten zur topischen Behandlung von peripheren Durchblutungsstörungen
CA2264178A1 (en) * 1996-08-23 1998-02-26 Boehringer Mannheim Pharmaceuticals Corp. - Smithkline Beecham Corporati On Limited Partnership No.1 Method for inhibiting the expression of fas
ES2171839T3 (es) 1996-09-05 2002-09-16 Lilly Co Eli Analogos de carbazol como agonistas adrenergicos selectivos de beta3.
TR199900762T2 (xx) 1996-10-09 1999-07-21 Boehringer Mannheim Pharmaceuticals Cor.Smithkline Beecham Stresle aktifle�tirilen protein kinazlar�n�n engellenme y�ntemi.
US6730326B2 (en) 1997-07-22 2004-05-04 Roche Diagnostics Gmbh Thermodynamically stable modification of 1-(4-carbazolyl-oxy-3[2-(2-methoxyphenoxy)-ethylamino]-2-propanol process for its preparation and pharmaceutical compositions containing it
EP0893440A1 (en) * 1997-07-22 1999-01-27 Roche Diagnostics GmbH Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it
ZA989365B (en) * 1997-10-15 1999-04-15 Boehringer Mannheim Pharm Corp Preparation for treating alzheimer's disease
PL340456A1 (en) * 1997-11-12 2001-02-12 Boehringer Mannheim Pharm Corp Novel oral dosage form of carvedilol
HU9702209D0 (en) * 1997-11-24 1998-01-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical product
HU227441B1 (en) * 1997-11-24 2011-06-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Process for producing carvedilol, enantiomers and salts thereof
CO5011072A1 (es) 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
EP0968714A1 (de) * 1998-07-02 2000-01-05 Roche Diagnostics GmbH Verfahren zur Herstellung schnellauflösender pharmazeutischer Zubereitungen von schwerlöslichen Wirkstoffen
CN1151788C (zh) * 1998-04-09 2004-06-02 罗切诊断学有限公司 卡维地洛-盖仑制剂
US6664284B2 (en) 1998-07-23 2003-12-16 Roche Diagnostics Gmbh Stabilized carvedilol injection solution
DE19833119A1 (de) * 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Spritzfertige Injektionslösungen enthaltend Carvedilol
AU5251999A (en) 1998-08-04 2000-02-28 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
PE20001302A1 (es) 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
MY125942A (en) 1999-09-07 2006-09-29 Upjohn Co Aminoalkoxy carbazoles for the treatment of cns diseases
EP1233768A1 (en) 1999-11-15 2002-08-28 Smithkline Beecham Carvedilol methanesulfonate
ES2227206T3 (es) * 2000-04-03 2005-04-01 F. Hoffmann-La Roche Ag Soluciones concentradas de carvedilol.
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
DK174645B1 (da) * 2000-05-18 2003-08-04 Gea Farmaceutisk Fabrik As Fremgangsmåde og mellemprodukter til fremstillingen af 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol, carvedilol og syreadditionssalte deraf
KR20030017569A (ko) * 2000-06-28 2003-03-03 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
EP1655285A1 (en) * 2000-06-28 2006-05-10 Teva Pharmaceutical Industries Ltd. Method for preparation of a crystalline form of carvedilol (form II)
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
GB0106953D0 (en) * 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
WO2002078692A1 (en) * 2001-04-02 2002-10-10 Smithkline Beecham Corporation Method of treatment
IN191028B (en, 2012) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
AU2002326391A1 (en) * 2001-07-13 2003-01-29 Smithkline Beecham Corporation Carvedilol polymorph
WO2003017046A2 (en) * 2001-08-14 2003-02-27 Variant Holdings, Llc. System for marketing goods and services utilizing computerized central and remote facilities
EP2957281A1 (en) * 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
AU2002338726B2 (en) * 2001-09-28 2007-03-15 F. Hoffmann-La Roche Ag Pseudopolymorphic forms of carvedilol
WO2003028718A1 (en) * 2001-10-01 2003-04-10 Smithkline Beecham Corporation Novel formulations of carvedilol
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
CN1298322C (zh) 2002-01-15 2007-02-07 特瓦制药工业有限公司 卡维地洛的结晶固体及其制备方法
JP2006500320A (ja) * 2002-04-30 2006-01-05 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール一クエン酸塩一水和物
CA2484621A1 (en) * 2002-05-03 2003-11-13 Smithkline Beecham Pharmco Puerto Rico, Inc. Carvedilol formulations
WO2003092626A2 (en) * 2002-05-03 2003-11-13 Smithkline Beecham Pharmco Puerto Rico, Inc. Carvedilol pharmasolve solvate
WO2004002472A1 (en) 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol hydrobromide
US7268156B2 (en) * 2002-06-27 2007-09-11 Sb Pharmco Puerto Rico Inc. Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
US20040152756A1 (en) * 2002-07-15 2004-08-05 Wei Chen Carvedilol polymorph
KR20040010306A (ko) * 2002-07-22 2004-01-31 (주)나노하이브리드 이트라코나졸, 사이클로스포린 또는 카르베딜올과 층상형규산염의 혼성체 및 그 제조 방법
PL375713A1 (en) 2002-08-19 2005-12-12 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
US6632832B1 (en) 2002-09-10 2003-10-14 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
SK285547B6 (sk) * 2002-11-08 2007-03-01 Zentiva, A. S. Spôsob prípravy Carvedilolu
AU2003275953A1 (en) * 2002-11-08 2004-06-07 Egalet A/S Controlled release carvedilol compositions
EP1615888A1 (en) * 2003-04-21 2006-01-18 Matrix Laboratories Ltd Process for the preparation of carvedilol form-ii
AU2004242777B2 (en) * 2003-05-30 2011-05-12 Ranbaxy Laboratories Limited Substituted pyrrole derivatives and their use as HMG-Co inhibitors
US7482471B2 (en) * 2003-06-20 2009-01-27 Sun Pharmaceutical Industries Limited Process for preparation of 1-[9H-carbazol-4-yloxy]-3-[{2-(2-(-methoxy)phenoxy)-ethyl}-amino]-propan-2-ol
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
WO2005051325A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol compositions methods of treatment and delivery
EP1686986A4 (en) * 2003-11-25 2009-05-27 Sb Pharmco Inc CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT
US20050175695A1 (en) * 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
WO2005115981A2 (en) * 2004-04-22 2005-12-08 Usv Limited A process for the preparation of 1-(9h-carbazol-4-yloxy)-3-2-(-methoxyphenoxy)-ethyl amino-propan-2-ol
GB0411273D0 (en) * 2004-05-20 2004-06-23 Cipla Ltd Process and product
WO2006060122A2 (en) * 2004-11-30 2006-06-08 Artesian Therapeutics, Inc. Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase
CN100591668C (zh) * 2004-12-09 2010-02-24 Zach系统股份公司 制备卡维地洛及其对映异构体的方法
US20070027202A1 (en) * 2005-06-07 2007-02-01 Ashok Kumar Process for the preparation of carvedilol and its salts
EP1781611A1 (en) * 2005-06-09 2007-05-09 Teva Pharmaceutical Industries Ltd. Crystalline forms of carvedilol and processes for their preparation
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
AU2006300877A1 (en) 2005-10-13 2007-04-19 Orchid Research Laboratories Limited Heterocyclic compounds as pSTAT3/IL-6 inhibitors
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
KR101329112B1 (ko) * 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
CL2007000667A1 (es) * 2006-03-14 2008-03-14 Ranbaxi Lab Ltd Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
WO2007144785A2 (en) * 2006-03-26 2007-12-21 Uti Limited Partnership Ryanodine receptor inhibitors and methods relating thereto
US8022094B2 (en) * 2006-06-28 2011-09-20 Teva Pharmaceutical Industries Ltd. Carvedilol phosphate
JP2009543773A (ja) * 2006-07-14 2009-12-10 ランバクシー ラボラトリーズ リミテッド ＨＭＧ−ＣｏＡレダクターゼ阻害剤の多形体及びその使用
WO2008038301A1 (en) * 2006-09-26 2008-04-03 Morepen Laboratories Limited A process for the preparation of carvedilol
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
US20080292695A1 (en) * 2006-12-01 2008-11-27 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
EP2094643B1 (en) 2006-12-01 2012-02-29 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2008084494A1 (en) * 2007-01-08 2008-07-17 Matrix Laboratories Limited Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same
CA2674536C (en) * 2007-01-16 2016-07-26 Egalet A/S Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
CZ302357B6 (cs) * 2007-01-26 2011-03-30 Zentiva, A. S. Zpusob cištení Carvedilolu
US20080207726A1 (en) * 2007-02-26 2008-08-28 Santiago Ini Process for the purification of carvedilol or its salts thereof
US20080249317A1 (en) * 2007-04-04 2008-10-09 Apotex Inc. Novel amorphous form of carvedilol phosphate and processes for the preparation thereof
WO2008142703A1 (en) * 2007-05-17 2008-11-27 Wanbury Limited A novel cost effective process for production of carvedilol phosphate
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
EP2195292B1 (en) * 2007-08-21 2013-10-02 Lupin Ltd. Stable amorphous form of carvedilol dihydrogen phosphate with stabilizer
US20090076283A1 (en) * 2007-09-07 2009-03-19 Scinopharm Taiwan Ltd. Method of crystallizing carvedilol phosphate and the product thereof
US20090076116A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched carvediolo
US20090111998A1 (en) * 2007-10-25 2009-04-30 Srinivas Reddy Gade Process for the preparation of carvedilol dihydrogen phosphate hemihydrate and pharmaceutical compositions thereof
WO2009110004A1 (en) 2008-03-04 2009-09-11 Lupin Limited Stable pharmaceutical compositions qf carvedilol
WO2009115906A2 (en) * 2008-03-19 2009-09-24 Cadila Pharmaceuticals Ltd. An improved process for preparation of carvedilol involving halohydrin derivative
WO2009115902A1 (en) * 2008-03-19 2009-09-24 Cadila Pharmaceuticals Ltd. Process for the preparation of carvedilol via silyl protection of substituted amine
US20110015247A1 (en) * 2008-04-04 2011-01-20 Shodhana Laboratories Limited Novel crystalline form of carvedilol dihydrogen phosphate and related processes
US7763645B2 (en) * 2008-05-23 2010-07-27 Wanbury Limited Carvedilol dihydrogen phosphate monohydrate
WO2010092589A2 (en) * 2008-05-26 2010-08-19 Alkem Laboratories Ltd. Process for preparation of amorphous carvedilol phosphate
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
NZ603579A (en) 2009-06-24 2014-02-28 Egalet Ltd Controlled release formulations
TWI415604B (zh) 2009-09-29 2013-11-21 Tsh Biopharm Corp Ltd 調控釋放卡菲蒂羅劑型
US20110229564A1 (en) * 2010-03-22 2011-09-22 Amneal Pharmaceuticals, L.L.C. Pharmaceutical Compositions Of Carvedilol Salts And Process For Preparation Thereof
IN2014CN04350A (en, 2012) 2011-12-16 2015-09-04 3M Innovative Properties Co
CA2877183A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
US8492426B1 (en) * 2012-07-12 2013-07-23 Anis Ahmad Use of carvedilol for treatment of diabetes mellitus
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
US10357476B1 (en) 2018-10-30 2019-07-23 Anis Ahmad Method for treating coronary artery disease
HUE069590T2 (hu) 2019-01-18 2025-03-28 Astrazeneca Ab PCSK9-gátló 6'-[[(1s,3s)-3-[[5-(difluormetoxi)-2-pirimidinil]amino]ciklopentil]amino][1(2h ),3'-bipiridin]-2-on és alkalmazására szolgáló eljárások
CN111170997A (zh) * 2019-12-31 2020-05-19 广州医科大学 咔唑类化合物及其制备方法和应用
CN113372260A (zh) * 2021-07-05 2021-09-10 大连蒙迪科技有限公司 一种卡维地洛杂质的合成方法
CN115960032A (zh) * 2021-10-08 2023-04-14 复旦大学 具有β-arrestin偏向性激动活性的芳氧丙醇胺类β-肾上腺素受体配基及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1834015A (en) * 1929-06-29 1931-12-01 Gen Aniline Works Inc Manufacture of hydroxy carbazoles
DE1152107B (de) * 1956-06-27 1963-08-01 Chem Fab Promonta G M B H Verfahren zur Herstellung von basisch substituierten Carbazolderivaten und deren Salzen
US3932424A (en) * 1970-06-15 1976-01-13 Richardson-Merrell Inc. Bis-basic ethers of carbazole
BE789072A (fr) * 1971-09-23 1973-03-21 Astra Laekemedel Ab Composes abaissant le taux de lipides du serum et leur obtention
AT336176B (de) * 1971-12-10 1977-04-25 Sandoz Ag Verfahren zur herstellung eines pharmazeutischen praparates
US3975398A (en) * 1973-08-01 1976-08-17 Boehringer Mannheim G.M.B.H. 9-Substituted 3-aminocarbazole compounds
DE2339396C2 (de) * 1973-08-03 1984-06-28 Boehringer Mannheim Gmbh, 6800 Mannheim N-substituierte 1-Amino-3-phenoxypropan-2-ole, deren Salze, Verfahren zu deren Herstellung sowie Arzneimittel, die diese Verbindungen enthalten
DE2424523A1 (de) * 1974-05-21 1975-12-11 Boehringer Mannheim Gmbh Neue 1,2,3,4-tetrahydrocarbazol-derivate und verfahren zu deren herstellung
US4076829A (en) * 1974-11-16 1978-02-28 Boehringer Mannheim Gmbh Aminopropanol compounds and compositions for the treatment of cardiac and circulatory diseases
US4152446A (en) * 1974-11-16 1979-05-01 Boehringer Mannheim Gmbh Aminopropanol compounds and compositions for the treatment of cardiac and circulatory diseases
DE2454406A1 (de) * 1974-11-16 1976-05-20 Boehringer Mannheim Gmbh Neue aminopropanol-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4115409A (en) * 1975-12-05 1978-09-19 Imperial Chemical Industries Limited Alkanolamine derivatives
GB1508208A (en) * 1975-12-05 1978-04-19 Ici Ltd Amide derivatives

Also Published As

Publication number Publication date
JPS54157558A (en) 1979-12-12
JPS63258416A (ja) 1988-10-25
DK154555B (da) 1988-11-28
FI70406C (fi) 1986-09-19
IL57020A (en) 1982-07-30
SU810079A3 (ru) 1981-02-28
CA1129416A (en) 1982-08-10
CS420091A3 (en) 1992-04-15
LT2628B (lt) 1994-04-25
HK2385A (en) 1985-01-18
IL57020A0 (en) 1979-07-25
NL930110I1 (nl) 1993-10-18
EP0004920B1 (de) 1981-08-05
HU179433B (en) 1982-10-28
DE2960553D1 (en) 1981-11-05
DK141979A (da) 1979-10-14
ATA276279A (de) 1984-01-15
EP0004920A1 (de) 1979-10-31
JPH0123462B2 (en, 2012) 1989-05-02
LU88320I2 (de) 1994-05-04
AT375639B (de) 1984-08-27
US4503067A (en) 1985-03-05
BG61419B2 (bg) 1997-07-31
FI791142A7 (fi) 1979-10-14
DD143607A5 (de) 1980-09-03
MX9203380A (es) 1992-09-01
ZA791732B (en) 1980-05-28
CS227007B2 (en) 1984-04-16
AU522975B2 (en) 1982-07-08
DE2815926A1 (de) 1979-10-18
ES479396A1 (es) 1980-04-16
AU4582079A (en) 1979-10-18
DK154555C (da) 1989-06-19
FI70406B (fi) 1986-03-27
SG52284G (en) 1985-03-29

Similar Documents

Publication Publication Date Title
NL930110I2 (nl) Carbazolyl-(4)-oxypropanolamine-derivaten, werkwijze ter bereiding daarvan en geneesmiddelen, die deze verbindingen bevatten.
NL7902489A (nl) Cycloalkyltriazoolderivaten met farmacologische wer- king, werkwijze ter bereiding van deze verbindingen, alsmede gedoseerde farmaceutische preparaten die zo'n verbinding bevatten.
NL930106I2 (nl) Ergolineverbindingen, hun bereiding en farmaceutische preparaten die ze bevatten.
NL990027I2 (nl) Bisindoolverbindingen, farmaceutische preparaten die hen bevatten en werkwijze voor hun bereiding.
NL191738C (nl) ML-236B-derivaten, werkwijze voor hun bereiding en farmaceutische preparaten, die deze derivaten bevatten.
NL190552C (nl) 1-Fenyl-4-alkyl-7,8-dialkoxy-5H-2,3-benzodiazepinederivaten en farmaceutische preparaten, die deze bevatten.
NL7800363A (nl) Nieuwe 4.9-dieen-11b-gesubstitueerde steroid- derivaten, werkwijze ter bereiding daarvan en farmaceutische preparaten, die deze steroid- derivaten bevatten.
IT8019049A0 (it) Composti 2 penem, metodo per laloro preparazione e composizioni farmaceutiche contenenti tali composti.
NL930026I1 (nl) 3-Allyl-7,8-dihydroxy-6-Halo-1-(4-hydroxyfenyl)-2,3,4,5,-tetrahydro-1H-3-Benzazepine derivaten werkwijze voor de bereiding daarvan en samenstellingen die deze bevatten
NL990010I1 (nl) Ä3HÜ-imidazo-Ä5,1-dÜ-1,2,3,5-tetrazine-4-on derivaten en farmaceutische samenstellingen, die deze derivaten bevatten.
NL7714066A (nl) 1.4-dihydropyridineverbindingen, werkwijze voor de bereiding daarvan en farmaceutische prepara- ten, die deze verbindingen bevatten.
NL174144C (nl) 6,7-dialkoxy-4-piperidinochinazolinen, alsmede werkwijze ter bereiding van dergelijke verbindingen en farmaceutische preparaten, die deze verbindingen bevatten.
NL7706433A (nl) 4-trifluormethylbenzoezuurderivaten en werkwij- ze voor de bereiding daarvan, alsmede farma- ceutische mengsels, die deze bevatten.
IT1193847B (it) Composizione farmaceutica contenente 3,4-di-idro-3-osso-2-chinossaline
NL7811050A (nl) Nieuwe chinazolinederivaten, werkwijze ter bereiding daarvan alsmede farmaceutische preparaten die zo'n verbinding bevatten.
NL188645C (nl) 1-azaxanthon-3-carbonzuurverbindingen en farmaceutische preparaten die deze verbindingen bevatten.
NL7807974A (nl) Thiatetrahydrofuranverbindingen, alsmede werkwijze voor de bereiding en toepassing daarvan en composities, die dergelijke verbindingen bevatten.
NL187397C (nl) Farmaceutische preparaten, 20,21-dinoreburnamenineverbindingen daarvoor en werkwijze voor hun bereiding.
FI791424A7 (fi) Substituoidut 8-hydroksi-1-fenyyli-2,3,4,5-tetrahydro-1H-3- bentsatsepiinit, menetelmä niiden valmistamiseksi jniitä sisältävät farmaseuttiset seokset.
FI792206A7 (fi) Menetelmä uusien oksadiatsolopyrimidiini-johdannaisten valmistamiseksi.
NL7807440A (nl) Derivaten van 2,4 - diamino -5- benzyl-pyrimidine; werkwijze voor de bereiding daarvan; geneesmiddel dat dergelijke verbindingen bevat.
FI793445A7 (fi) Menetelmä uusien, aryylitrifluorietanolia sisältävien farmaseuttisten koostumusten valmivalmistamiseksi.
NL7714205A (nl) Werkwijze ter bereiding van 5-fluoruracilderi- vaten en farmaceutische preparaten die deze derivaten bevatten.
NL7900721A (nl) Nieuwe derivaten van 1-naftylazijnzuur, werkwijze ter bereiding daarvan en farmaceutische preparaten, die deze verbindingen bevatten.
NL187168C (nl) 3 beta-oxygesubstitueerde-18 beta-olean-30-carboxyderivaten, werkwijze ter bereiding daarvan en farmaceutische preparaten welke een of meer van deze verbindingen bevatten.